03.06.15
CorMatrix Cardiovascular Inc., a developer of biomaterials and medical devices, has received eight new patents from the U.S. Patent and Trademark Office related to its augmented extracellular matrix (ECM) bioscaffolds.
The new patents include U.S. patent numbers: 8,568,761; 8,753,885; 8,734,841; 8,642,084; 8,771,737; 8,734,842; 8,753,886; 8,735,155; 8,771,737; 8,784,891; 8,785,197 and 8,785,198.
The augmented ECM bioscaffold tissue structures comprise various materials, including, but not limited to, small intestine, urinary bladder, liver, stomach, placental, and heart tissue, that are augmented with a variety of selective bioactive components, such as GAGs, FGF-2, TGF-α, TFG-β, VEGF, cytokines and DNA. The augmented ECM bioscaffolds, when administered to damaged tissue, induce stem cell proliferation and differentiation of stem cells into cardiomyocytes and, thereby, angiogenesis and remodeling of the damaged tissue.
“Since our founding in 2001, CorMatrix has focused on bringing innovation to the science of ECM and ECM technologies. Our success in securing these patents will help us to expand the effectiveness, scope, and potential of ECM while guiding us in other restorative tissue advancements. We continue to pursue these and other patents globally with the intent of creating innovative healthcare products patients receive as part of their treatment, and the ultimate goal of improving their quality of life,” said David Camp, CEO and co-founder of Roswell, Ga.-based CorMatrix.
The company claims it has more than 230 pending U.S. and foreign patent applications directed to various ECM-based compositions and structures. In addition to the recently issued patents for CorMatrix’s novel augmented injectable extracellular matrix bioscaffolds, in the last two years more than 30 U.S. and foreign patents have issued for ECM-based compositions and structures, company officials said.
CorMatrix is privately held medical device company developing biomaterial devices that harness the body’s own innate ability to repair damaged cardiac and vascular tissues. The company has U.S. clearance and European registration for its ECM technology.
According to the company, since its launch in 2006, CorMatrix ECM has been used at more than 825 hospitals in the United States and has been implanted in more than 100,000 cardiac procedures.
The new patents include U.S. patent numbers: 8,568,761; 8,753,885; 8,734,841; 8,642,084; 8,771,737; 8,734,842; 8,753,886; 8,735,155; 8,771,737; 8,784,891; 8,785,197 and 8,785,198.
The augmented ECM bioscaffold tissue structures comprise various materials, including, but not limited to, small intestine, urinary bladder, liver, stomach, placental, and heart tissue, that are augmented with a variety of selective bioactive components, such as GAGs, FGF-2, TGF-α, TFG-β, VEGF, cytokines and DNA. The augmented ECM bioscaffolds, when administered to damaged tissue, induce stem cell proliferation and differentiation of stem cells into cardiomyocytes and, thereby, angiogenesis and remodeling of the damaged tissue.
“Since our founding in 2001, CorMatrix has focused on bringing innovation to the science of ECM and ECM technologies. Our success in securing these patents will help us to expand the effectiveness, scope, and potential of ECM while guiding us in other restorative tissue advancements. We continue to pursue these and other patents globally with the intent of creating innovative healthcare products patients receive as part of their treatment, and the ultimate goal of improving their quality of life,” said David Camp, CEO and co-founder of Roswell, Ga.-based CorMatrix.
The company claims it has more than 230 pending U.S. and foreign patent applications directed to various ECM-based compositions and structures. In addition to the recently issued patents for CorMatrix’s novel augmented injectable extracellular matrix bioscaffolds, in the last two years more than 30 U.S. and foreign patents have issued for ECM-based compositions and structures, company officials said.
CorMatrix is privately held medical device company developing biomaterial devices that harness the body’s own innate ability to repair damaged cardiac and vascular tissues. The company has U.S. clearance and European registration for its ECM technology.
According to the company, since its launch in 2006, CorMatrix ECM has been used at more than 825 hospitals in the United States and has been implanted in more than 100,000 cardiac procedures.